Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer

BACKGROUND: Neratinib is an irreversible pan-HER tyrosine kinase inhibitor approved for HER2-positive early-stage and metastatic breast cancer. Diarrhea is the most frequent side effect and the most common reason for early discontinuation. The phase II CONTROL trial investigated antidiarrheal prophy...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Arlene, Ruiz-Borrego, Manuel, Marx, Gavin, Chien, A. Jo, Rugo, Hope S., Brufsky, Adam, Thirlwell, Michael, Trudeau, Maureen, Bose, Ron, García-Sáenz, José A., Egle, Daniel, Pistilli, Barbara, Wassermann, Johanna, Cheong, Kerry A., Schnappauf, Benjamin, Semsek, Dieter, Singer, Christian F., Foruzan, Navid, DiPrimeo, Daniel, McCulloch, Leanne, Hurvitz, Sara A., Barcenas, Carlos H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982309/
https://www.ncbi.nlm.nih.gov/pubmed/36702070
http://dx.doi.org/10.1016/j.breast.2022.12.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982309/
https://www.ncbi.nlm.nih.gov/pubmed/36702070
http://dx.doi.org/10.1016/j.breast.2022.12.003

Ejemplares similares